Name (Synonyms) | Correlation | |
---|---|---|
drug2150 | SCB-2019 with AS03 adjuvant Wiki | 1.00 |
drug2149 | SCB-2019 Wiki | 1.00 |
drug3018 | survey Wiki | 0.41 |
Name (Synonyms) | Correlation | |
---|---|---|
D045169 | Severe Acute Respiratory Syndrome NIH | 0.05 |
D018352 | Coronavirus Infections NIH | 0.04 |
Name (Synonyms) | Correlation |
---|
There is one clinical trial.
This is a randomized, double blind, placebo controlled, first-in-human (FIH) study to assess safety, reactogenicity, and immunogenicity of SCB-2019 at multiple dose levels, administered as 2 injections IM in healthy subjects. Each study vaccine dose level will be evaluated with and without adjuvant.
Description: Geometric mean titer (GMT). Geometric mean ratio (GMR). Seroconversion rate (SCR).
Measure: Immunogenicity(Anti-SCB-2019 Antibody Titers) Time: Day 1 to Day 184Description: Geometric mean titer (GMT). Geometric mean ratio (GMR). Seroconversion rate (SCR).
Measure: Immunogenicity( serum anti SARS-CoV-2 neutralizing antibody titers (ACE2 receptor-based) ) Time: Day 1 to Day 184Description: Geometric mean titer (GMT). Geometric mean ratio (GMR). Seroconversion rate (SCR).
Measure: Immunogenicity(serum anti SARS-CoV-2 neutralizing antibody titers (cell based) ) Time: Day 1 to Day 184Description: Geometric mean titer (GMT). Geometric mean ratio (GMR). Seroconversion rate (SCR).
Measure: Immunogenicity(serum anti SARS-CoV-2 whole virus antibody titers) Time: Day 1 to Day 184Description: Geometric mean titer (GMT). Geometric mean ratio (GMR). Seroconversion rate (SCR).
Measure: Antibody kinetics of each SCB 2019 vaccine formulation after first and second doses Time: Day 1 to Day 184